ALK and non-small cell lung carcinoma: Nevertheless, novel therapeutic strategies capable of circumventing EMT underpinning short-lived responses to various cytotoxic and targeted drugs including multiple-generation ALK–TKIs remain an unmet clinical need in ALK-rearranged NSCLC [79,80,81,82,83,84].